Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Buy This Tech Stock on the Dip Before Earnings for Big Growth?

Published 11/30/2021, 06:00 AM
Updated 07/09/2023, 06:31 AM

Veeva Systems (NYSE:VEEV) Inc. VEEV offers cloud-based solutions for the pharmaceutical and life sciences industries. The stock has crushed the broader tech sector over the last five years and its growth outlook remains strong.

But VEEV is trading nearly 15% below its records heading into its Q3 earnings release that’s due out after the closing bell on Wednesday, December 1. And investors might want to consider buying Veeva stock on the dip for longer-term tech growth.

The Basics

Veeva sells cloud-based offerings geared toward the pharmaceutical and life sciences industries. The company helps its roughly 1,100 clients improve and streamline their critical business functions, with software and services geared to everything from research and development and regulatory processes to training and nearly anything else a firm in these fields might need.

VEEV’s clients include biotech startups, pharmaceutical powerhouses, and beyond. The firm’s overall goal is to help “companies of all sizes bring products to market faster and more efficiently, and maintain compliance.”

The California-based firm’s offerings have caught on around the industry and its subscription-focused offerings have helped it grow rapidly and steadily. Veeva has grown its revenue by at least 25% every year since it went public in 2013, including 33% sales growth last year (its fiscal 2021).

VEEV topped our Q2 earnings and revenue estimates in September, with sales up 29% and adjusted earnings 30% higher. Zacks estimates call for Veeva to continue its impressive top-line growth trend, with fiscal 2022 revenue set to climb by 25% to reach $1.83 billion. The company is also projected to post 21% higher adjusted earnings.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Looking ahead to next year, Veeva is projected to post another 15% earnings growth on nearly 20% higher revenue. The company has also consistently beaten our bottom-line estimates and its overall adjusted EPS outlook has improved since its last report to help it grab a Zacks Rank #2 (Buy) right now.

Image Source: Zacks Investment Research

Bottom Line

Veeva stock has skyrocketed 520% in the last five years and 105% in the past 24 months to easily outpace its industry during both periods. A recent slowdown might set up an enticing buying opportunity, with VEEV up only 6% in the last year vs. its industry’s 18% climb.

The stock closed regular trading Monday about 14% below its August records. The recent drop does have Veeva sitting below both its 50-day and 200-day moving averages recently.

But its current Zacks consensus price target represents over 17% upside to its current levels and the stock began to pop above oversold RSI levels (30 or under) last week. And Veeva stock could still have plenty of runway left since it only hovers at 38. Meanwhile, the Nasdaq 100-tracking QQQ ETF is at 60, after falling below overbought RSI levels early last week.

Veeva’s pullback has cooled off its valuation as well, with it trading at 30% discounts to its own year-long highs in terms of both forward earnings and sales. Plus, 13 of the 17 brokerage recommendations Zacks has for the stock are either “Strong Buys” or “Buys.” On top of that, VEEV boasts a solid balance sheet and its cloud software and services cater to vital industries.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative.

See Zacks’ Hottest Tech IPOs Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Veeva Systems Inc. (VEEV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Oops! Bad call on this one!
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.